Sign up to save your podcasts
Or
Share How this founder raised $230MM in capital
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How this founder raised $230MM in capital
Carter Cliff is the CEO of Papillon Therapeutics. Papillon is advancing genetic medicines for life threatening conditions including Cystinosis, Friedreich's ataxia, Danon disease, and Alzheimer's disease, and the company is currently partnered with Novartis on a phase 1/2 trial for their lead candidate in cystinosis. Carter has a multi-decade career in biotech and life sciences and is also a
venture partner at Saisei Ventures where he helps launch biotechnology companies, and has raised over $200MM in funding across various ventures.
Enjoy the show!
Disclaimers
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role
as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
View all episodes
By Tim Dougherty
4.3
33 ratings
Carter Cliff is the CEO of Papillon Therapeutics. Papillon is advancing genetic medicines for life threatening conditions including Cystinosis, Friedreich's ataxia, Danon disease, and Alzheimer's disease, and the company is currently partnered with Novartis on a phase 1/2 trial for their lead candidate in cystinosis. Carter has a multi-decade career in biotech and life sciences and is also a
venture partner at Saisei Ventures where he helps launch biotechnology companies, and has raised over $200MM in funding across various ventures.
Enjoy the show!
Disclaimers
The information contained in this website and podcast are purely informational and not considered investment recommendations. Tim Dougherty’s participation in Biotech Insights is separate and apart from his role
as an investment advisor representative. Nothing contained herein may be construed as a recommendation or endorsement of any of the companies discussed. Tim Dougherty has no financial affiliation with any of the companies mentioned in this communication. Tim Dougherty makes no representation that the information conveyed in this material is accurate and is under no obligation to update this information as changes occur.
More shows like Life Science and Biotech CEO stories
View all
TED Radio Hour
21,927 Listeners
The Readout Loud
316 Listeners
Biotech 2050 Podcast
61 Listeners
Biotech Hangout
18 Listeners
The Biotech Startups Podcast
22 Listeners